An investigation on behalf of investors in Charles River Laboratories International, Inc. (NYSE: CRL) shares over potential wrongdoing at Charles River Laboratories International, Inc. was announced and NYSE: CRL stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/08/2018 -- An investigation was announced for investors in shares of Charles River Laboratories International, Inc. (NYSE: CRL) concerning possible breaches of fiduciary duties by certain officers and directors at Charles River Laboratories.
Investors who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL) shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Charles River Laboratories International, Inc. directors breached their fiduciary duties.
Wilmington, MA based Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. Charles River Laboratories International, Inc. reported that its annual Total Revenue rose from over $1.68 billion in 2016 to over $1.85 billion in 2017 and that its Net Income declined from $156.36 million in 2016 to $125.44 million in 2017.
Shares of Charles River Laboratories International, Inc. (NYSE: CRL) rose from $67.20 per share in October 2016 to as high as $119.05 per share in October 2017.
On June 7, 2018, NYSE: CRL shares closed at $112.44 per share.
Those who purchased shares of Charles River Laboratories International, Inc. (NYSE: CRL), have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com